Galapagos begins Phase I clinical development of GLPG0259 drug for rheumatoid arthritis - Quick Facts (Nasdaq)

(RTTNews) - Galapagos NV (GLPYY.PK) said it commenced Phase I clinical development of candidate drug GLPG0259 for rheumatoid arthritis, or RA. The primary endpoints of phase I clinical trial will be to determine the safety, tolerability, and pharmacokinetics of the candidate drug GLPG0259.